HLN vs. SN, SGE, WHR, ANP, CLX, TPX, PNPL, LEG, ULVR, and BXP
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Smith & Nephew (SN), The Sage Group (SGE), Warehouse REIT (WHR), Anpario (ANP), Calnex Solutions (CLX), TPXimpact (TPX), Pineapple Power (PNPL), Legendary Investments (LEG), Unilever (ULVR), and Beximco Pharmaceuticals (BXP).
Haleon vs. Its Competitors
Smith & Nephew (LON:SN) and Haleon (LON:HLN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.
Smith & Nephew has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Haleon has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
62.2% of Smith & Nephew shares are held by institutional investors. Comparatively, 43.9% of Haleon shares are held by institutional investors. 0.2% of Smith & Nephew shares are held by company insiders. Comparatively, 10.7% of Haleon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Haleon has higher revenue and earnings than Smith & Nephew. Haleon is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
In the previous week, Smith & Nephew had 5 more articles in the media than Haleon. MarketBeat recorded 9 mentions for Smith & Nephew and 4 mentions for Haleon. Smith & Nephew's average media sentiment score of 0.59 beat Haleon's score of -0.17 indicating that Smith & Nephew is being referred to more favorably in the media.
Smith & Nephew presently has a consensus price target of GBX 1,379.33, indicating a potential upside of 1.95%. Haleon has a consensus price target of GBX 435, indicating a potential upside of 21.54%. Given Haleon's higher probable upside, analysts plainly believe Haleon is more favorable than Smith & Nephew.
Haleon has a net margin of 9.66% compared to Smith & Nephew's net margin of 5.41%. Haleon's return on equity of 6.54% beat Smith & Nephew's return on equity.
Smith & Nephew pays an annual dividend of GBX 29 per share and has a dividend yield of 2.1%. Haleon pays an annual dividend of GBX 6 per share and has a dividend yield of 1.7%. Smith & Nephew pays out 104.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Haleon pays out 50.5% of its earnings in the form of a dividend.
Summary
Smith & Nephew beats Haleon on 9 of the 17 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools
This page (LON:HLN) was last updated on 8/14/2025 by MarketBeat.com Staff